Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 ––Total ...
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback